Genentech/OSI Tarceva Shows Two-Month Survival Improvement Over Placebo
Executive Summary
Genentech/OSI's anti-EGFR agent Tarceva is associated with a two-month improvement in survival for refractory non-small cell lung cancer patients, according to pivotal trial data presented at the American Society of Clinical Oncology annual meeting in New Orleans June 7
You may also be interested in...
AstraZeneca Iressa Response Working, Company Says: Docs Move To Tarceva
AstraZeneca's efforts to promote Genentech/OSI's Tarceva as the first-choice epidermal growth factor receptor therapy are working, the company told FDA's Oncologic Drugs Advisory Committee March 4
AstraZeneca Iressa Response Working, Company Says: Docs Move To Tarceva
AstraZeneca's efforts to promote Genentech/OSI's Tarceva as the first-choice epidermal growth factor receptor therapy are working, the company told FDA's Oncologic Drugs Advisory Committee March 4
AstraZeneca To Revisit Iressa Dosing Following Failed Survival Study
Inappropriate dose selection is one issue AstraZeneca will examine following Iressa's failure to demonstrate a survival benefit in a Phase IV trial in refractory non-small cell lung cancer, CEO Tom McKillop indicated